 | Parts of this article (those related to lack of effectiveness against the Omicron variant) need to be updated. (January 2022) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL-6R |
| Clinical data | |
| Trade names | Kevzara |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617032 |
| License data | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% |
| Metabolism | likely proteases |
| Elimination half-life | 21 days (steady-state, estimated) |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6388H9918N1718O1998S44 |
| Molar mass | 144164.28 g·mol−1 |
  (what is this?) (verify) | |
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor.[6] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[7]
Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[8]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Arthritis". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ "Regulatory Decision Summary for Kevzara". Drug and Health Products Portal. 12 January 2017. Retrieved 13 April 2024.
- ^ "Kevzara- sarilumab injection, solution". DailyMed. 17 June 2024. Retrieved 26 August 2024.
- ^ "Kevzara EPAR". European Medicines Agency (EMA). 23 June 2017. Retrieved 26 August 2024.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab" (PDF). ama-assn.org. American Medical Association.
- ^ "Kevzara: Authorisation details". European Medicines Agency. Archived from the original on 27 September 2017. Retrieved 28 September 2017.
- ^ "Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis". regeneron.com (Press release). Paris & Tarrytown, New York: Regeneron. 12 July 2011.